Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma

Andrea L. Wiens, Sarah E. Martin, Elizabeth C. Bertsch, Gail Vance, Ryan A. Stohler, Liang Cheng, Sunil Badve, Eyas M. Hattab

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Context.-Metastatic breast cancer to the central nervous system (CNS) is second only to lung cancer metastasis to the CNS in frequency. Patients with triple-negative primary breast cancer and those with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer are at an increased risk for metastasis. Very little is known about predictive or prognostic variables once patients develop CNS metastases. Currently, therapeutic options are limited, with surgery generally offered primarily to those with solitary lesions. Objectives.-To determine the influence of molecular subtypes of metastatic breast cancer on survival from the time of CNS metastasis and to aid in the prognostic stratification of these patients. Design.-We identified 59 cases of metastatic breast cancer to the CNS and analyzed them for various demographic and clinicopathologic parameters. Tumors were categorized into molecular subtypes using immunohistochemical methods: luminal A [estrogen receptor (ER)+/Ki67low], luminal B (ER+/Ki67 high), intrinsic HER2 (ER -/HER2+), and triple-negative. Survival after CNS metastasis for each group was plotted using a Kaplan- Meier curve, and multivariate analysis was performed. Results.-Patients with metastases from luminal tumors had a statistically significant survival advantage when compared with those of the triple-negative phenotype. Importantly, survival among patients with luminal A and luminal B tumors was not significantly different. Similarly, patient's age, histologic grade, and number of lesions did not contribute to determining outcomes. Conclusions.-Estrogen receptor positivity (ie, luminal phenotype) of tumors appears to determine outcomes after development of metastases. In contrast, proliferation rate had little or no effect on the long-term survival. Understanding the biology of metastases can help stratify patients into prognostically meaningful categories and tailor treatment regimens for individual patients.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume138
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Central Nervous System
Breast Neoplasms
Neoplasm Metastasis
Survival
Estrogen Receptors
Neoplasms
Triple Negative Breast Neoplasms
Phenotype
Kaplan-Meier Estimate
Lung Neoplasms
Multivariate Analysis
Demography
Therapeutics
human ERBB2 protein

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. / Wiens, Andrea L.; Martin, Sarah E.; Bertsch, Elizabeth C.; Vance, Gail; Stohler, Ryan A.; Cheng, Liang; Badve, Sunil; Hattab, Eyas M.

In: Archives of Pathology and Laboratory Medicine, Vol. 138, No. 2, 02.2014, p. 175-181.

Research output: Contribution to journalArticle

@article{f7ea8cbc66b94f5d94501eb8c017d223,
title = "Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma",
abstract = "Context.-Metastatic breast cancer to the central nervous system (CNS) is second only to lung cancer metastasis to the CNS in frequency. Patients with triple-negative primary breast cancer and those with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer are at an increased risk for metastasis. Very little is known about predictive or prognostic variables once patients develop CNS metastases. Currently, therapeutic options are limited, with surgery generally offered primarily to those with solitary lesions. Objectives.-To determine the influence of molecular subtypes of metastatic breast cancer on survival from the time of CNS metastasis and to aid in the prognostic stratification of these patients. Design.-We identified 59 cases of metastatic breast cancer to the CNS and analyzed them for various demographic and clinicopathologic parameters. Tumors were categorized into molecular subtypes using immunohistochemical methods: luminal A [estrogen receptor (ER)+/Ki67low], luminal B (ER+/Ki67 high), intrinsic HER2 (ER -/HER2+), and triple-negative. Survival after CNS metastasis for each group was plotted using a Kaplan- Meier curve, and multivariate analysis was performed. Results.-Patients with metastases from luminal tumors had a statistically significant survival advantage when compared with those of the triple-negative phenotype. Importantly, survival among patients with luminal A and luminal B tumors was not significantly different. Similarly, patient's age, histologic grade, and number of lesions did not contribute to determining outcomes. Conclusions.-Estrogen receptor positivity (ie, luminal phenotype) of tumors appears to determine outcomes after development of metastases. In contrast, proliferation rate had little or no effect on the long-term survival. Understanding the biology of metastases can help stratify patients into prognostically meaningful categories and tailor treatment regimens for individual patients.",
author = "Wiens, {Andrea L.} and Martin, {Sarah E.} and Bertsch, {Elizabeth C.} and Gail Vance and Stohler, {Ryan A.} and Liang Cheng and Sunil Badve and Hattab, {Eyas M.}",
year = "2014",
month = "2",
doi = "10.5858/arpa.2012-0541-OA",
language = "English",
volume = "138",
pages = "175--181",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "2",

}

TY - JOUR

T1 - Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma

AU - Wiens, Andrea L.

AU - Martin, Sarah E.

AU - Bertsch, Elizabeth C.

AU - Vance, Gail

AU - Stohler, Ryan A.

AU - Cheng, Liang

AU - Badve, Sunil

AU - Hattab, Eyas M.

PY - 2014/2

Y1 - 2014/2

N2 - Context.-Metastatic breast cancer to the central nervous system (CNS) is second only to lung cancer metastasis to the CNS in frequency. Patients with triple-negative primary breast cancer and those with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer are at an increased risk for metastasis. Very little is known about predictive or prognostic variables once patients develop CNS metastases. Currently, therapeutic options are limited, with surgery generally offered primarily to those with solitary lesions. Objectives.-To determine the influence of molecular subtypes of metastatic breast cancer on survival from the time of CNS metastasis and to aid in the prognostic stratification of these patients. Design.-We identified 59 cases of metastatic breast cancer to the CNS and analyzed them for various demographic and clinicopathologic parameters. Tumors were categorized into molecular subtypes using immunohistochemical methods: luminal A [estrogen receptor (ER)+/Ki67low], luminal B (ER+/Ki67 high), intrinsic HER2 (ER -/HER2+), and triple-negative. Survival after CNS metastasis for each group was plotted using a Kaplan- Meier curve, and multivariate analysis was performed. Results.-Patients with metastases from luminal tumors had a statistically significant survival advantage when compared with those of the triple-negative phenotype. Importantly, survival among patients with luminal A and luminal B tumors was not significantly different. Similarly, patient's age, histologic grade, and number of lesions did not contribute to determining outcomes. Conclusions.-Estrogen receptor positivity (ie, luminal phenotype) of tumors appears to determine outcomes after development of metastases. In contrast, proliferation rate had little or no effect on the long-term survival. Understanding the biology of metastases can help stratify patients into prognostically meaningful categories and tailor treatment regimens for individual patients.

AB - Context.-Metastatic breast cancer to the central nervous system (CNS) is second only to lung cancer metastasis to the CNS in frequency. Patients with triple-negative primary breast cancer and those with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer are at an increased risk for metastasis. Very little is known about predictive or prognostic variables once patients develop CNS metastases. Currently, therapeutic options are limited, with surgery generally offered primarily to those with solitary lesions. Objectives.-To determine the influence of molecular subtypes of metastatic breast cancer on survival from the time of CNS metastasis and to aid in the prognostic stratification of these patients. Design.-We identified 59 cases of metastatic breast cancer to the CNS and analyzed them for various demographic and clinicopathologic parameters. Tumors were categorized into molecular subtypes using immunohistochemical methods: luminal A [estrogen receptor (ER)+/Ki67low], luminal B (ER+/Ki67 high), intrinsic HER2 (ER -/HER2+), and triple-negative. Survival after CNS metastasis for each group was plotted using a Kaplan- Meier curve, and multivariate analysis was performed. Results.-Patients with metastases from luminal tumors had a statistically significant survival advantage when compared with those of the triple-negative phenotype. Importantly, survival among patients with luminal A and luminal B tumors was not significantly different. Similarly, patient's age, histologic grade, and number of lesions did not contribute to determining outcomes. Conclusions.-Estrogen receptor positivity (ie, luminal phenotype) of tumors appears to determine outcomes after development of metastases. In contrast, proliferation rate had little or no effect on the long-term survival. Understanding the biology of metastases can help stratify patients into prognostically meaningful categories and tailor treatment regimens for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=84893656018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893656018&partnerID=8YFLogxK

U2 - 10.5858/arpa.2012-0541-OA

DO - 10.5858/arpa.2012-0541-OA

M3 - Article

VL - 138

SP - 175

EP - 181

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 2

ER -